MA50800A - Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson - Google Patents

Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson

Info

Publication number: MA50800A
Authority: MA; Morocco
Prior art keywords: catecholamine; parkinson; disease; treatment; new
Prior art date: 2017-11-24

Application number

MA050800A

Other languages

English (en)

Inventor

Klaus Gjervig Jensen

Martin Juhl

Lisbet Kværnø

Jørgensen Morten

Original Assignee

H Lundbeck As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-11-24

Filing date

2018-11-23

Publication date

2020-09-30

2018-11-23 Application filed by H Lundbeck As filed Critical H Lundbeck As

2020-09-30 Publication of MA50800A publication Critical patent/MA50800A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Addiction (AREA)
Crystallography & Structural Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

MA050800A 2017-11-24 2018-11-23 Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson MA50800A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA201700674		2017-11-24

Publications (1)

Publication Number	Publication Date
MA50800A true MA50800A (fr)	2020-09-30

Family

ID=64661284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050800A MA50800A (fr)	2017-11-24	2018-11-23	Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson

Country Status (25)

Country	Link
US (5)	US10729710B2 (fr)
EP (1)	EP3713933A1 (fr)
JP (4)	JP7320507B2 (fr)
KR (1)	KR102712887B1 (fr)
CN (3)	CN111386267B (fr)
AR (1)	AR113908A1 (fr)
AU (2)	AU2018371193B2 (fr)
BR (1)	BR112019014981A2 (fr)
CA (1)	CA3082757A1 (fr)
CL (1)	CL2020001343A1 (fr)
CO (1)	CO2020006224A2 (fr)
CR (1)	CR20200225A (fr)
EA (1)	EA202090987A8 (fr)
EC (1)	ECSP20030074A (fr)
GE (2)	GEP20227446B (fr)
IL (1)	IL274648B2 (fr)
JO (1)	JOP20200114A1 (fr)
MA (1)	MA50800A (fr)
MX (2)	MX2020005366A (fr)
PE (1)	PE20211290A1 (fr)
PH (1)	PH12020550631A1 (fr)
SG (1)	SG11202004461YA (fr)
TW (1)	TWI816716B (fr)
UA (1)	UA127575C2 (fr)
WO (1)	WO2019101917A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2020005366A (es) *	2017-11-24	2020-08-13	H Lundbeck As	Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
US11104697B2 (en) *	2019-05-20	2021-08-31	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) *	2019-05-20	2021-09-28	H. Lundbeck A/S	Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) *	2019-05-20	2021-09-07	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en)	2019-05-20	2021-11-09	H. Lundbeck A/S	Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
WO2020234275A1 (fr)	2019-05-21	2020-11-26	H. Lundbeck A/S	Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de maladies de parkinson
WO2020234277A1 (fr)	2019-05-21	2020-11-26	H. Lundbeck A/S	Promédicaments de carbamate de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
CN113727974B (zh)	2019-05-21	2025-01-07	H.隆德贝克有限公司	用于治疗帕金森病的新儿茶酚胺前药
EP3972970A1 (fr) *	2019-05-21	2022-03-30	H. Lundbeck A/S	Nouveaux promédicaments à base de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
JP2023552699A (ja) *	2020-11-17	2023-12-19	ハー・ルンドベック・アクチエゼルスカベット	パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CA3250415A1 (fr)	2022-04-25	2023-11-02	Håkan Wikström	Nouveaux composés de 1, 2, 3, 4, 4a, 5, 6, 7, 8, 9, 10, 10a-dodécahydrobenzo [g] quinolin-6-ol et leurs utilisations
AU2023262467A1 (en)	2022-04-25	2024-10-31	Integrative Research Laboratories Sweden Ab	NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023208867A1 (fr)	2022-04-25	2023-11-02	Integrative Research Laboratories Sweden Ab	Nouveaux composés de 1,2,3,4,4a,5,8,9,10,10a-décahydrobenzo[g]quinolin-6(7h)-one et leurs utilisations
JP2025520542A (ja)	2022-06-15	2025-07-03	エバーニューロファーマゲーエムベーハー	アポモルヒネプロドラッグおよびその使用
WO2025078574A1 (fr)	2023-10-12	2025-04-17	Integrative Research Laboratories Sweden Ab	Nouveaux esters de composés 1,2,3,4,4a,5,6,7,8,9,10,10a-dodécahydrobenzo[g]quinolin-6-ol et leurs utilisations
WO2025078571A1 (fr)	2023-10-12	2025-04-17	Integrative Research Laboratories Sweden Ab	Nouveaux carbonates et carbamates de composés 1,2,3,4,4a,5,6,7,8,9,10,10a-dodécahydrobenzo[g]quinolin-6-ol et leurs utilisations

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3132171A (en)	1962-06-18	1964-05-05	Strong Cobb Arner Inc	3, 4-diphosphatophenyl-alanine and process for making same
US4543256A (en)	1982-03-17	1985-09-24	Northeastern University	(-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
ATE56958T1 (de)	1981-10-16	1990-10-15	Sandoz Ag	1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolinderivate mit pharmazeutischer wirkung.
PH22782A (en)	1983-02-01	1988-12-12	Sandoz Ltd	Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
JPS60172975A (ja)	1984-02-15	1985-09-06	Sumitomo Chem Co Ltd	エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en)	1986-07-11	1988-01-13	Glaxo Group Ltd	Amine derivatives
IT1226727B (it)	1988-07-29	1991-02-05	Simes	Farmaci precursori della dopamina.
ATE118216T1 (de)	1989-04-20	1995-02-15	Zambon Spa	Dopamin-medikament-vorstufe.
WO1990012574A1 (fr)	1989-04-25	1990-11-01	Northeastern University	Composes agonistes de la dopamine
IT1271411B (it)	1993-09-14	1997-05-28	Zambon Spa	Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en)	1993-12-21	1999-09-21	Sandoz Ltd.	Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en)	1995-07-07	1999-05-01	Novartis Ag	Benzo[g]quinoline derivatives
IT1289979B1 (it)	1997-02-26	1998-10-19	Zambon Spa	5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
GB9902938D0 (en)	1999-02-10	1999-03-31	Novartis Ag	Organic compounds
CO5261532A1 (es)	1999-11-15	2003-03-31	Novartis Ag	Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
US6506765B2 (en)	2000-04-07	2003-01-14	Tap Pharmaceutical Products, Inc.	Apomorphine derivatives and methods for their use
SE0001438D0 (sv)	2000-04-18	2000-04-18	Axon Chemicals Bv	New chemical compounds and their use in therapy
AU8824201A (en)	2000-08-11	2002-02-25	Bristol Myers Squibb Co	Process for the preparation of dinapsoline
SE0102036D0 (sv)	2001-06-08	2001-06-08	Axon Biochemicals Bv	Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv)	2000-08-17	2000-08-17	Axon Biochemicals Bv	New aporphine esters and in their use in therapy
PE20030240A1 (es)	2001-07-09	2003-04-16	Novartis Ag	DERIVADOS DE BENZO [g] QUINOLINA
DE60220800D1 (de)	2001-08-10	2007-08-02	Purdue Research Foundation	Chirales dinapsolin
EG24415A (en)	2002-03-07	2009-05-25	Novartis Ag	Quinoline derivatives
BR0308567A (pt)	2002-03-19	2007-01-09	Michael Holick	derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
WO2004052841A1 (fr)	2002-12-06	2004-06-24	Xenoport, Inc.	Promedicamemts de carbidopa et leurs utilisations
US20070155720A1 (en)	2003-12-23	2007-07-05	Darpharma, Inc.	Co-administration of dopamine-receptor binding compounds
US20070254906A1 (en)	2004-07-21	2007-11-01	Darpharma, Inc.	Method of Administration of Dopamine Receptor Agonists
WO2006056604A1 (fr)	2004-11-25	2006-06-01	Evolva Ag	Derives de levodopa glycosyl, procedes de preparation et d'utilisation associes
US8129530B2 (en)	2007-08-31	2012-03-06	H. Lundbeck A/S	Catecholamine derivatives and prodrugs thereof
TWI404702B (zh)	2007-08-31	2013-08-11	Lundbeck & Co As H	兒茶酚胺衍生物和其前藥
EP2303851A1 (fr)	2008-06-27	2011-04-06	H. Lundbeck A/S	Nouvelles amines phénoliques et catécholiques et leurs promédicaments
TW201035054A (en)	2009-02-27	2010-10-01	Lundbeck & Co As H	Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) *	2009-02-27	2010-10-16	Lundbeck & Co As H	Treatment of dyskinesia related disorders
EP2557079A1 (fr)	2011-08-09	2013-02-13	Nestec S.A.	Synthèse de catéchine et conjugués d'épicatéchine
DE102011112496A1 (de)	2011-09-07	2013-03-07	Thanares GmbH	4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh)	2012-07-23	2018-03-02	上海弈柯莱生物医药科技有限公司	灯盏花乙素及其类似物的制备方法
GB201319768D0 (en)	2013-11-08	2013-12-25	Glycosynth Ltd	Naphthalene derived chromogenic enzyme substrates
JP6567049B2 (ja)	2014-10-21	2019-08-28	アッヴィ・インコーポレイテッド	カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
CN105218606B (zh)	2015-10-19	2017-12-01	昆明理工大学	一种制备灯盏乙素的方法
EP3445346A1 (fr)	2016-04-20	2019-02-27	AbbVie Inc.	Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation
US9920342B2 (en)	2016-05-17	2018-03-20	Divi's Laboratories Limited	Process for the preparation of Droxidopa
MX2020005366A (es)	2017-11-24	2020-08-13	H Lundbeck As	Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
US11104697B2 (en)	2019-05-20	2021-08-31	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en)	2019-05-20	2021-11-09	H. Lundbeck A/S	Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en)	2019-05-20	2021-09-28	H. Lundbeck A/S	Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en)	2019-05-20	2021-09-07	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972970A1 (fr)	2019-05-21	2022-03-30	H. Lundbeck A/S	Nouveaux promédicaments à base de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
CN113727974B (zh)	2019-05-21	2025-01-07	H.隆德贝克有限公司	用于治疗帕金森病的新儿茶酚胺前药
WO2020234277A1 (fr)	2019-05-21	2020-11-26	H. Lundbeck A/S	Promédicaments de carbamate de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
WO2020234275A1 (fr)	2019-05-21	2020-11-26	H. Lundbeck A/S	Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de maladies de parkinson
JP2023552699A (ja)	2020-11-17	2023-12-19	ハー・ルンドベック・アクチエゼルスカベット	パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7693430B2 (ja) *	2021-07-15	2025-06-17	株式会社日立製作所	運行提案システム、及び運行提案作成方法

2018
- 2018-11-23 MX MX2020005366A patent/MX2020005366A/es unknown
- 2018-11-23 CN CN201880075320.XA patent/CN111386267B/zh active Active
- 2018-11-23 BR BR112019014981A patent/BR112019014981A2/pt unknown
- 2018-11-23 EA EA202090987A patent/EA202090987A8/ru unknown
- 2018-11-23 CN CN202311564635.XA patent/CN117653649A/zh active Pending
- 2018-11-23 IL IL274648A patent/IL274648B2/en unknown
- 2018-11-23 EP EP18815537.8A patent/EP3713933A1/fr active Pending
- 2018-11-23 CR CR20200225A patent/CR20200225A/es unknown
- 2018-11-23 US US16/198,917 patent/US10729710B2/en active Active
- 2018-11-23 KR KR1020207014479A patent/KR102712887B1/ko active Active
- 2018-11-23 MA MA050800A patent/MA50800A/fr unknown
- 2018-11-23 JP JP2020528199A patent/JP7320507B2/ja active Active
- 2018-11-23 GE GEAP201815342A patent/GEP20227446B/en unknown
- 2018-11-23 CN CN202311564502.2A patent/CN117599073A/zh active Pending
- 2018-11-23 GE GEAP202215342A patent/GEAP202215342A/en unknown
- 2018-11-23 AU AU2018371193A patent/AU2018371193B2/en active Active
- 2018-11-23 CA CA3082757A patent/CA3082757A1/fr active Pending
- 2018-11-23 JO JOP/2020/0114A patent/JOP20200114A1/ar unknown
- 2018-11-23 WO PCT/EP2018/082361 patent/WO2019101917A1/fr not_active Ceased
- 2018-11-23 SG SG11202004461YA patent/SG11202004461YA/en unknown
- 2018-11-23 PE PE2020000566A patent/PE20211290A1/es unknown
- 2018-11-23 UA UAA202003060A patent/UA127575C2/uk unknown
- 2018-11-23 AR ARP180103436A patent/AR113908A1/es unknown
- 2018-11-23 TW TW107141799A patent/TWI816716B/zh active
2020
- 2020-05-12 US US16/872,802 patent/US11110110B2/en active Active
- 2020-05-14 PH PH12020550631A patent/PH12020550631A1/en unknown
- 2020-05-20 CL CL2020001343A patent/CL2020001343A1/es unknown
- 2020-05-21 CO CONC2020/0006224A patent/CO2020006224A2/es unknown
- 2020-06-03 EC ECSENADI202030074A patent/ECSP20030074A/es unknown
- 2020-07-13 MX MX2022016276A patent/MX2022016276A/es unknown
2021
- 2021-07-28 US US17/386,686 patent/US11707476B2/en active Active
2023
- 2023-01-31 JP JP2023013012A patent/JP7320684B2/ja active Active
- 2023-03-21 AU AU2023201741A patent/AU2023201741A1/en not_active Abandoned
- 2023-06-06 US US18/330,293 patent/US12226428B2/en active Active
- 2023-07-24 JP JP2023119694A patent/JP2023145580A/ja active Pending
- 2023-07-24 JP JP2023119693A patent/JP7443606B2/ja active Active
2025
- 2025-01-15 US US19/021,529 patent/US20250381208A1/en active Pending

Also Published As

Publication number	Publication date
GEP20227446B (en)	2022-12-12
US12226428B2 (en)	2025-02-18
IL274648A (en)	2020-06-30
AU2023201741A1 (en)	2023-04-20
US20250381208A1 (en)	2025-12-18
EP3713933A1 (fr)	2020-09-30
JP2023055830A (ja)	2023-04-18
CN117599073A (zh)	2024-02-27
UA127575C2 (uk)	2023-10-18
CN117653649A (zh)	2024-03-08
CA3082757A1 (fr)	2019-05-31
JP2023145579A (ja)	2023-10-11
AU2018371193B2 (en)	2022-12-22
CN111386267B (zh)	2023-12-12
CN111386267A (zh)	2020-07-07
CO2020006224A2 (es)	2020-05-29
IL274648B2 (en)	2024-10-01
US20220257623A1 (en)	2022-08-18
US11110110B2 (en)	2021-09-07
TWI816716B (zh)	2023-10-01
IL274648B1 (en)	2024-06-01
NZ764717A (en)	2024-08-30
US10729710B2 (en)	2020-08-04
WO2019101917A1 (fr)	2019-05-31
JOP20200114A1 (ar)	2020-05-17
BR112019014981A2 (pt)	2020-04-07
EA202090987A8 (ru)	2020-09-29
JP7320684B2 (ja)	2023-08-03
US11707476B2 (en)	2023-07-25
US20200338102A1 (en)	2020-10-29
SG11202004461YA (en)	2020-06-29
AU2018371193A1 (en)	2020-06-11
JP7320507B2 (ja)	2023-08-03
MX2020005366A (es)	2020-08-13
CL2020001343A1 (es)	2020-09-25
US20240156851A1 (en)	2024-05-16
CR20200225A (es)	2020-07-25
RU2020116419A (ru)	2021-12-27
ECSP20030074A (es)	2020-07-31
PE20211290A1 (es)	2021-07-20
JP2023145580A (ja)	2023-10-11
US20190160083A1 (en)	2019-05-30
JP2021504345A (ja)	2021-02-15
KR20200092955A (ko)	2020-08-04
PH12020550631A1 (en)	2021-02-22
JP7443606B2 (ja)	2024-03-05
AR113908A1 (es)	2020-06-24
TW201924693A (zh)	2019-07-01
MX2022016276A (es)	2023-02-09
GEAP202215342A (en)	2022-07-11
EA202090987A1 (ru)	2020-08-07
KR102712887B1 (ko)	2024-10-02

Publication	Publication Date	Title
MA50800A (fr)	2020-09-30	Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
MA49402A (fr)	2020-04-22	Polynucléotides aadc pour le traitement de la maladie de parkinson
EP3405215A4 (fr)	2019-08-28	Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
EP3528852A4 (fr)	2020-06-03	Méthodes et compositions pour le traitement de la maladie de fabry
MA47688A (fr)	2020-01-08	Compositions utiles dans le traitement de l'amyotrophie spinale
MA52631A (fr)	2021-03-24	Compositions et méthodes pour le traitement de la maladie de parkinson
EP3820537A4 (fr)	2022-04-13	Vecteurs de thérapie génique pour le traitement de la maladie de danon
EP3762505A4 (fr)	2021-12-01	Compositions et méthodes pour le traitement de la maladie de parkinson
EP3592841A4 (fr)	2021-01-06	Procédés et compositions de traitement de cancers à l'aide d'acides nucléiques antisens
EP3402533A4 (fr)	2019-07-24	Méthodes et compositions pour le traitement d'une maladie neurologique
MA50905A (fr)	2020-09-23	Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
EP3600305A4 (fr)	2021-06-16	Formulations d'alcaloïde berbérine dans la prévention et/ou le traitement d'une maladie infectieuse
EP3419622A4 (fr)	2019-07-10	Traitement d'une maladie neurodégénérative de l'oeil à l'aide de pridopidine
EP3672587A4 (fr)	2021-05-19	Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
HUE059387T2 (hu)	2022-11-28	Parkinson-kór kezelése
MA50233A (fr)	2020-07-22	Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
MA53562A (fr)	2021-07-14	Polythérapie destinée au traitement d'une maladie hépatique
EP3694579A4 (fr)	2021-07-07	Administration automatisée à base clinique de substances de traitement à l'oreille interne
MA53739A (fr)	2021-12-29	Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés
EP4069700A4 (fr)	2023-05-17	Macrocycles destinés à être utilisés dans le traitement d'une maladie
EP3654961A4 (fr)	2021-04-21	Méthodes et compositions pour le traitement de la douleur à l'aide de la capsaïcine
EP3833435A4 (fr)	2022-05-11	Détermination de la maladie de parkinson
IL259710A (en)	2018-07-31	Compositions and methods of treatment for mvid and related diseases
EP3402778A4 (fr)	2019-12-18	Procédés et compositions médicamenteuses destinés au traitement de la maladie de lyme
EP3802568A4 (fr)	2022-07-13	Agents thérapeutiques peptidiques pour le traitement de la maladie d'alzheimer et d'états apparentés